First report on the safety and efficacy of an extended half‐life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A
K. Hampton; P. Chowdary; S. Dunkley; S. Ehrenforth; L. Jacobsen; A. Neff; E. Santagostino; J. Sathar; H. Takedani; C. M. Takemoto; C. Négrier
Author Information: Department of Cardiovascular Science
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.